vs

Side-by-side financial comparison of Clean Energy Fuels Corp. (CLNE) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Clean Energy Fuels Corp. is the larger business by last-quarter revenue ($112.3M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, Clean Energy Fuels Corp. posted the faster year-over-year revenue change (2.7% vs -36.9%). Clean Energy Fuels Corp. produced more free cash flow last quarter ($6.5M vs $-6.6M). Over the past eight quarters, Clean Energy Fuels Corp.'s revenue compounded faster (4.1% CAGR vs -34.4%).

Bloom Energy is an American public company that designs and manufactures solid oxide fuel cells (SOFCs) which independently produce electricity onsite for power generation in data centers, manufacturing, and other commercial sectors. Founded in 2001 and headquartered in San Jose, California; its fuel cell technology generates electricity through a chemical conversion process, which differs from most other power sources reliant on combustion, and can use natural gas, biogas or hydrogen as fuel...

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

CLNE vs MED — Head-to-Head

Bigger by revenue
CLNE
CLNE
1.5× larger
CLNE
$112.3M
$75.1M
MED
Growing faster (revenue YoY)
CLNE
CLNE
+39.6% gap
CLNE
2.7%
-36.9%
MED
More free cash flow
CLNE
CLNE
$13.1M more FCF
CLNE
$6.5M
$-6.6M
MED
Faster 2-yr revenue CAGR
CLNE
CLNE
Annualised
CLNE
4.1%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLNE
CLNE
MED
MED
Revenue
$112.3M
$75.1M
Net Profit
$-43.0M
Gross Margin
69.4%
Operating Margin
-9.5%
-10.4%
Net Margin
-38.3%
Revenue YoY
2.7%
-36.9%
Net Profit YoY
-42.6%
EPS (diluted)
$-0.21
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLNE
CLNE
MED
MED
Q4 25
$112.3M
$75.1M
Q3 25
$106.1M
$89.4M
Q2 25
$102.6M
$105.6M
Q1 25
$103.8M
$115.7M
Q4 24
$109.3M
$119.0M
Q3 24
$104.9M
$140.2M
Q2 24
$98.0M
$168.6M
Q1 24
$103.7M
$174.7M
Net Profit
CLNE
CLNE
MED
MED
Q4 25
$-43.0M
Q3 25
$-23.8M
$-2.3M
Q2 25
$-20.2M
$2.5M
Q1 25
$-135.0M
$-772.0K
Q4 24
$-30.2M
Q3 24
$-18.2M
$1.1M
Q2 24
$-16.3M
$-8.2M
Q1 24
$-18.4M
$8.3M
Gross Margin
CLNE
CLNE
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
CLNE
CLNE
MED
MED
Q4 25
-9.5%
-10.4%
Q3 25
-12.8%
-4.6%
Q2 25
-9.0%
-1.0%
Q1 25
-121.7%
-1.1%
Q4 24
-11.8%
0.6%
Q3 24
-8.1%
1.5%
Q2 24
-5.7%
-4.7%
Q1 24
-9.0%
4.5%
Net Margin
CLNE
CLNE
MED
MED
Q4 25
-38.3%
Q3 25
-22.4%
-2.5%
Q2 25
-19.7%
2.3%
Q1 25
-130.1%
-0.7%
Q4 24
-27.6%
Q3 24
-17.3%
0.8%
Q2 24
-16.6%
-4.8%
Q1 24
-17.8%
4.8%
EPS (diluted)
CLNE
CLNE
MED
MED
Q4 25
$-0.21
$-1.64
Q3 25
$-0.11
$-0.21
Q2 25
$-0.09
$0.22
Q1 25
$-0.60
$-0.07
Q4 24
$-0.14
$0.08
Q3 24
$-0.08
$0.10
Q2 24
$-0.07
$-0.75
Q1 24
$-0.08
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLNE
CLNE
MED
MED
Cash + ST InvestmentsLiquidity on hand
$156.1M
$167.3M
Total DebtLower is stronger
$226.8M
Stockholders' EquityBook value
$559.4M
$198.9M
Total Assets
$1.1B
$248.0M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLNE
CLNE
MED
MED
Q4 25
$156.1M
$167.3M
Q3 25
$232.2M
$173.5M
Q2 25
$240.8M
$162.7M
Q1 25
$226.6M
$164.6M
Q4 24
$217.5M
$162.3M
Q3 24
$243.5M
$170.0M
Q2 24
$249.3M
$163.5M
Q1 24
$248.9M
$156.4M
Total Debt
CLNE
CLNE
MED
MED
Q4 25
$226.8M
Q3 25
$284.3M
Q2 25
$277.9M
Q1 25
$271.6M
Q4 24
$265.4M
Q3 24
$264.1M
Q2 24
$263.0M
Q1 24
$262.0M
Stockholders' Equity
CLNE
CLNE
MED
MED
Q4 25
$559.4M
$198.9M
Q3 25
$585.2M
$214.7M
Q2 25
$590.8M
$216.0M
Q1 25
$596.7M
$211.0M
Q4 24
$713.3M
$210.1M
Q3 24
$724.8M
$207.3M
Q2 24
$723.0M
$205.3M
Q1 24
$722.9M
$211.0M
Total Assets
CLNE
CLNE
MED
MED
Q4 25
$1.1B
$248.0M
Q3 25
$1.1B
$268.2M
Q2 25
$1.1B
$269.3M
Q1 25
$1.1B
$280.0M
Q4 24
$1.2B
$284.2M
Q3 24
$1.2B
$291.2M
Q2 24
$1.2B
$293.5M
Q1 24
$1.2B
$302.8M
Debt / Equity
CLNE
CLNE
MED
MED
Q4 25
0.41×
Q3 25
0.49×
Q2 25
0.47×
Q1 25
0.46×
Q4 24
0.37×
Q3 24
0.36×
Q2 24
0.36×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLNE
CLNE
MED
MED
Operating Cash FlowLast quarter
$13.1M
$-5.3M
Free Cash FlowOCF − Capex
$6.5M
$-6.6M
FCF MarginFCF / Revenue
5.8%
-8.8%
Capex IntensityCapex / Revenue
5.9%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$59.9M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLNE
CLNE
MED
MED
Q4 25
$13.1M
$-5.3M
Q3 25
$13.1M
$12.1M
Q2 25
$35.9M
$-3.4M
Q1 25
$23.4M
$3.4M
Q4 24
$21.9M
$-4.9M
Q3 24
$21.4M
$9.1M
Q2 24
$18.8M
$13.1M
Q1 24
$2.6M
$7.3M
Free Cash Flow
CLNE
CLNE
MED
MED
Q4 25
$6.5M
$-6.6M
Q3 25
$6.5M
$10.8M
Q2 25
$30.9M
$-4.8M
Q1 25
$15.9M
$1.9M
Q4 24
$10.3M
$-7.2M
Q3 24
$42.0K
$7.7M
Q2 24
$4.8M
$11.1M
Q1 24
$-15.6M
$5.4M
FCF Margin
CLNE
CLNE
MED
MED
Q4 25
5.8%
-8.8%
Q3 25
6.1%
12.0%
Q2 25
30.2%
-4.5%
Q1 25
15.4%
1.6%
Q4 24
9.5%
-6.1%
Q3 24
0.0%
5.5%
Q2 24
4.9%
6.6%
Q1 24
-15.1%
3.1%
Capex Intensity
CLNE
CLNE
MED
MED
Q4 25
5.9%
1.8%
Q3 25
6.2%
1.5%
Q2 25
4.8%
1.3%
Q1 25
7.2%
1.3%
Q4 24
10.5%
1.9%
Q3 24
20.3%
1.0%
Q2 24
14.2%
1.1%
Q1 24
17.6%
1.1%
Cash Conversion
CLNE
CLNE
MED
MED
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLNE
CLNE

Volume Related Fuel Sales$73.6M66%
Services$15.1M13%
Station Construction Sales$10.7M9%
Volume Related Renewable Identification Number Credits$9.5M8%
Volume Related Low Carbon Fuel Standard Credits$3.4M3%

MED
MED

Segment breakdown not available.

Related Comparisons